

## DAFTAR PUSTAKA

- Akdis M MD PhD, Altunbulakli CA MSc, Azkur K DVM, Costa RA MSc, Cramer R, et al. Interleukins ( from IL-1 to IL-38), transforming growth factor  $\beta$ , and receptors, functions, and roles in diseases. *J allergy clin immunol.* 2016; 138 (4) : 984-1010
- Alpdogan O, van den Brink MR. IL-7 and IL-15 : Therapeutic Cytokines for Immunodeficiency. *Trends Immunol* (2005) 26(1):56–64
- Amiruddin, M, D. 2012 Penyakit kusta sebuah pendekatan klinis, Brillian Internasional, Makassar
- Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. 2008. *Genes & Development.* 22:1276– 1312
- Antunes SL, Motta E, de Almeida SM, Gallo ME, Nery JA, Lenzi HL. Distinct patterns of microvasculature in the cutaneous lesions of leprosy. *Int J Lepr Other Mycobact Dis.* 2000;68:143–151
- Arora M, Katoch K, Natrajan M, Kamal R, Yadav VS. Changing profile of disease in leprosy patients diagnosed in a tertiary care centre during years 1995-2000. *Indian J Lepr.* 2008;80:257-65
- Appasamy PM. Biological and clinical implications of interleukin-7 and lymphopoiesis. *Cytokines Cell Mol Ther* 1999;5:25–39.
- Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in patients with leprosy. *Infection and immunity.* 1992;60(4):1441-1446.

Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, Deshpande S. Circulating cytokine profiles in leprosy patients. *Lepr Rev* 2007;78:223-30.

Bhandarkar SS, Cohen C, Kuruwila M, Rea TH, Mackelfresh JB, Lee DJ, et al. Angiogenesis in cutaneous lesions of leprosy: implications for treatment. *Arch Dermatol.* 2007;143:1527–29.

Bilik L, Demir B, Cicek D. Leprosy reactions. *Intech open. Turki:* 2017:81-91  
Bikker A, Hack CE, Lafeber FPJG, Roon JAG. Interleukin-7 : a key mediator in T cell-driven autoimmunity. *Current Pharmaceutical Design.* 2012;18:1-10

Bikker A, van der Wurff-Jacobs KMG, Kruize AA, Peters RP, Bijlsma JWJ, Lafeber FPJG, van Roon JAG: IL-7-activated T-cells and monocytes drive B cell activation in patients with primary Sjogren's syndrome. *Ann Rheum Dis.* 2011;70(2):63

Brown DM, Hong SP, Farrell CL, Pierce GF, Khouri R. Platelet-derived growth factor BB induces functional vascular anastomoses in vivo. *Proc natl acad.* 1995;92:5920-24

Bryceson, A. & E.Pfaltzgraff, R. 2002, *Leprosy*, London, Churchill Livingstone.  
Carmeliet P . Angiogenesis in life, disease and medicine. *Nature.* 2005; 438: 932-936

Chen D, Tang T-X, Deng H, Yang X-P and Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis. *Front. Immunol.*2021;12:747324

Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti- TNF antibodies in

- patients with rheumatoid arthritis. *J Clin Invest.*1994; 94: 749-60.
- Danese S, Dejana E, Fiocchi C. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. *J Immunol.* 2007;178: 6017-22.
- El-Khawalany M, Shaaban D, Sultan M, Alsalam FA. Inhibition of angiogenesis as a new therapeutic target in the treatment of lepromatous leprosy. *Clinical, Cosmetic and Investigational Dermatology.* 2012;5 1–6
- Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. *J. Mol. Med.* 1999;77:527–43.
- Fitness J, Tosh K, Hill A. Genetic of susceptibility to leprosy. *Genes and Immunity.* 2002;3: 441-53
- Fretto LJ, Snape AJ, Tomlinson JE, Seroogy JJ, Wolf DL, et.al. Mechanism of platelet-derived growth factor AA, AB, and BB binding to  $\alpha$  and  $\beta$  PDGF receptor. *The journal of biological chemistry.* 1993;268(5):3625-31
- Flesch IE, Hess JH, Kaufmann SH. NADPH diaphorase staining suggests a transient and localized contribution of nitric oxide to host defence against an intracellular pathogen in situ. *Int Immunol.*1994;6:1751-7
- Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. *Blood* 2002; 99: 3892-904.
- Giliani S, Mori L, de Saint BG, Le DF, Rodriguez-Perez C, et.al. Interleukin-7 receptor alpha (IL-7R $\alpha$ ) deficiency: cellular and molecular bases: analysis of clinical, immunological, and molecular features in 16 novel patients. *Immunol Rev.* 2005 ;203:110-126.
- Goel S, Duda DG, Xu L, Munn LL, Boucher Y et al. Normalization of the vasculature for treatment of cancer and other diseases. *Physiol Rev.* 2011;91: 1071-121.
- Gonzalez-Quintial R, Lawson BR, Scatizzi JC, Craft J, Kono DH, Baccala R, et al. Systemic autoimmunity and lymphoproliferation are associated

with excess IL-7 and inhibit by IL-7R $\alpha$  blockade. *PLoS One*. 2011;6:e27528.

Gulia A, Fried I, Massone C. New insights in the pathogenesis and genetics of leprosy. *Med Rep*. 2010;2:30.

Hatta M, and Smits H. Detection of *Salmonella thypi* by Nested Polymerase Chain Reaction in Blood, Urine dan Stool Samples. *Am J.Med.Hyg*. 2007; 76(1):139-1

Hartgring S AY, Willis CR, Bijlsma J WJ, Lafeber F PJG, Roon J AG. Interleukin-7 aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. *Arthritis Research & Therapy*.2012, 14:R137

Health profil of Indonesia 2019. Kementerian Kesehatan RI.2019

Heldin, C.H.; Eriksson, U.; Ostman, A. New members of the platelet-derived growth factor family of mitogens. *Arch Biochem Biophys*. 2002;398: 284-90.

Huggenberger R, Detmar M. The cutaneous vascular system in chronic skin inflammation. The predictive value of mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients ( U-MDT/CT-BR). *Plos Neglected Tropical Diseases*. 2017. 11(2)

Iyer A,Eijk M, Silva E, Hatta M, Faver W, Aerts JM et al. Increased chitotriosidase activity in serum of leprosy patients : Association with bacillary leprosy. *Clinical Immunology*.2009;131:501-9

Iyer A, Hatta M, Usman R, Luiten S, Oskam L et al. Serum levels of interferon  $\gamma$ , tumour necrosis factor- $\alpha$ ,soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. *Clinical and Experimental Immunology*. 2007;150:210-16

Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. *Trans R Soc Trop Med Hyg*. 2008; 102(4):329–37.

- Kahawita IP, Walker S, Lockwood DN. Leprosy type 1 reactions and erythema nodosum leprosum. *An Bras Dermatol.* 2008;83:75- 82.
- Kaplan G. Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions. *Leprosy Review.* 2000;71:117-120
- Katoch, V.M. 2004. Advance in the diagnosis and treatment of leprosy. *Expert reviews in molecular medicine* 4:1-14
- Kifayet A, Shahid F, Lucas S, Hussain R. Erythema nodosum leprosum is associated with upregulation of polyclonal IgG1 antibody synthesis. *Clin Exp Immunol* 1996;106:447- 53.
- Kumar BS, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. *Int J Lepr Other Mycobact Dis.* 2004; 72:125–33.
- Kumar B, Kar K.M. Text book of Leprosy. Indian Association of Leprologists. The Health Science Publisher. India. 2010. 424-431
- Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM: Interleukin 7 regulates the survival and generation of memory CD4 cells. *J Exp Med.* 2003;198:1797-1806.
- Lastoria JC, Abreu MA. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects - part 1. *Anais Brasileiros de Dermatologia.* 2014;89:205–18.
- Lockwood, D. N. J. 2004 Leprosy. dalam Burn, T., Breathnach, S., Cox, N. & Griffiths, C. (Eds.) *Rook's Textbook of Dermatology.* 7<sup>th</sup> ed. USA, Blackwell Science.
- Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. *Immunol.* 2012;24:218–24.
- Mackall CL, Fry TJ, Gress RE. The biology of IL-7 for therapeutic application.

Nat

Rev Immunol.2011; 11: 330-42.

Manandhar R, LeMaster JW, Rohce PW. Risk factor for erythema nodosum leprosum. *Int J Lepr.*1999;67:270-8

Masaki T, McGlinchey A, Cholewa-Waclaw J, Qu J, Tomlinson SR, et al. Innate immune response precedes Mycobacterium leprae-induced reprogramming of adult Schwann cells. *Cell Reprogram.* 2014;16:9-17.

Massone C, Belachew WA, Schettini A. Histopathology of the lepromatous skin biopsy. *Clinics in Dermatology.* 2015;33:38–45.

Mitsodoerfer M, Lee Y, Jager A, Kim HJ, Korn T, K Jay et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. *PNAS.* 2010;107:32

Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, Sampaio EP: Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). *Scand J Immunol.*1999;50:541-49.

Moschella S. An update on the diagnosis and treatment of leprosy. *J Am Acad Dermatol.*2004;51:417– 26.

Naafs B. Current views on Reaction in Leprosy. *Indian J Lepr.* 2000; 72 (1) : 97 – 122.

Naafs B. Treatment of leprosy: Science or politics? *Tropical Medicine & International Health.* 2006;11:268-278.

Nath I, Saini C, Valluri VL. Immunology of leprosy and diagnostic challenges. *Clin. Dermatol.* 2015:90-8.

Negera E, Bobosha K, Walker SL, Endale B, Howe R, Aseffa A, Dockrell HM and Lockwood DN. New Insight into the Pathogenesis of Erythema Nodosum Leprosum: The Role of Activated Memory T-Cells. *Front. Immunol.*2017; 8:1149.

Nogueira M.R, Latini A.C. The involvement of endothelial mediators in leprosy. *Mem Inst Oswaldo Cruz.* 2016;111(10):635-41

- Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. *Virulence*. 2013; 4(6): 507-16.
- Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. *Indian J Dermatol Venereol Leprol*. 2013; 79(6):739–49
- Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: An 11-year cohort study in Hyderabad, India. *The American Journal of Tropical Medicine and Hygiene*. 2006;74:868-879
- Polycarpou A, Walker SL, Lockwood DN. A systematic review of immunological studies of erythema nodosum leprosum. *Front Immunol*. 2017;8:233
- Prabhu S, Shenoi SD, Pai SB, Sripathi H. Erythema nodosum leprosum as the presenting feature in multibacillary leprosy. *Dermatology Online Journal*. 2009;15:15
- Prameswari R, Listiawan MY, Rosita C. Peran TNF- $\alpha$  pada imunopatogenesis ENL dan Kontribusinya pada Penatalaksanaan ENL. *FK Unair*. 2012; 24(1): 43-48.
- Raica M, Cimpean AM. Platelet-derived growth factor or receptors axis as target for antitumor and antiangiogenic therapy. *Pharmaceuticals* 2010;3:572-99
- Rodrigues LC, Lockwood D. Leprosy now: epidemiology, progress, challenges, and research gaps. *Lancet Infect Dis*. 2011; 11(6):464–70
- Roon JA, Glaudem KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumor necrosis factor  $\alpha$  and Th1 cytokine production in joints of patients with rheumatoid arthritis. *Ann Rheum Dis* 2003;62:113–119
- Rusyati LM, Hatta M, Widiana IG, Adiguna MS, Wardana M et al. Higher Treg FoxP3 and TGF- $\beta$  mRNA expression in type 2 reaction ENL (Erythema Nodosum Leprosum) Patients in *Mycobacterium leprae* infection. *The open Microbiology Journal*. 2020;14:304-9
- Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, et al. The

influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. *J Infect Dis.* 1993

- Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN. Pentoxifylline decreases *in vivo* and *in vitro* tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). *Clin Exp Immunol.* 1998;111:300–8.
- Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor- $\alpha$  and interleukin-1  $\beta$  during leprosy reactional states. *Clin Exp Immunol* 1991;84:103-8.
- Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RT, Williams DL: The Continuing Challenges of Leprosy. *Clin Microbiol Rev.* 2006;19:339-381.
- Scollard DM, Chaduvula MV, Martinez A, Fowlkes N, Nath I, Stryjewska BM, et al. Increased CXC ligand 10 levels and gene expression in type 1 leprosy reactions. *Clin Vaccine Immunol.* 2011; 18 (6):947–53
- Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. Epidemiologic characteristics of leprosy reactions. *Int J Lepr Other Mycobact Dis.* 1994; 62(4):559–67.
- Sengupta U. Immunopathology of Leprosy (Symposium paper). *Indian J Lepr.* 2000;72: 381-91
- Sieling PA, Sakimura L, Uyemura K, et al. IL-7 in the cell-mediated immune response to a human pathogen. *J Immunol.* 1995; 154: 2775-83.
- Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of IL-7 in humans increases *in vivo* TCR repertoire diversity by preferential expansion of naive T cell subsets. *J Exp Med.* 2008;205:1701-1714.
- Stefani MM, Guerra JG, Sousa ALM, Costa MB, Oliveira ML, et al. Potential plasma markers of type 1 and 2 leprosy reactions: a preliminary report. Brazil: *BMC Infectious Diseases.* 2009;9:75
- Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL, Brazilian Leprosy Study Group: *In situ* type 1 cytokine gene expression and mechanisms associated



- with early leprosy progression. *J Infect Dis.*2003;188:1024-31.
- Vasir B, Avigan D, Wu Z, et al. Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. *J Immunol.* 2005; 174: 2376-86
- Vilani-Moreno FR, Brito-de-Souza VN, Silva SUR, Barbosa AS, Sartori BG, Campanelli AP, et al. Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker. *Indian J Dermatol Venereol Leprol* 2021;87:190-8.
- Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. *Leprosy Review.* 2007;78:197-215
- Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. *Annu Rev Immunol.*2009;27:29-60
- WHO. Global leprosy (Hansen disease) update,2019. Time to step-up prevention initiatives. *Wkly. Epidemiol. Rec.*2020;95:417-440
- Yamamura M, Wang XH, Ohmen JD, et al. Cytokine patterns of immunologically mediated tissue damage. *J Immunol.* 1992;149 :1470-81
- Yuwono T. Teori dan Aplikasi Polymerase Chain Reaction, Panduan Eksperimen PCR untuk Memecahkan Masalah Biologi Terkini. *Penerbit Andi*, Yogyakarta. 2006.